No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Trastuzumab emtansine monotherapy is noninferior to standard neoadjuvant therapy for ERBB2+ breast cancer

byTeddy Guo

September 8, 2021

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract: Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa

RelatedReports

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

The Scan by 2 Minute Medicine®

World Health Organization warns that one in six infections now antibiotic resistant

October 23, 2025

Population-based risk factors and geographical trends identified for vitiligo

Oncology

Increasing cancer incidence rates in younger and older adults worldwide

October 20, 2025

Blindness and visual impairment decreasing worldwide

AI Roundup

Punjab launches AI screening program this week

September 30, 2025

AI Roundup

2MM: AI Roundup –Lilly launches TuneLab AI drug discovery, smart wound healing bandage, and Punjab cancer screening [September 25th, 2025]

September 28, 2025

Updated USPSTF guidelines favor treatment of mild gestational diabetes

Novel macrophage-regulating cream demonstrated superior therapeutic efficacy for the treatment of diabetic foot ulcers compared to standard absorbent dressing

$The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor$

Biologic teclistamab shows promise in treatment of refractory multiple myeloma in phase 1 drug study

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Association of sleep duration with all-cause mortality in East Asian adults

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports